BeStock  
Stocks › Biotechnology › TRVI

Trevi Therapeutics TRVI

US equityMarket cap rank #2705Biotechnology
$13.35 −$0.37 (-2.70%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $13.35 0.00%
Open$13.58
Prev close$13.72
Day range$13.23 – $13.90
Volume2.09M
Market cap$1.90B
P/E (TTM)–
Dividend yield–

Price chart

Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, or Bollinger Bands for the same 20-day/2-standard-deviation channel used in the Technical signals table.

TRVI at a glance

Trevi Therapeutics stock (TRVI) sits at $13.35, down 2.70% today. The business is worth $1.90B in the market, good for #2705 of 3753 on our coverage list.

Over a full year the shares have ranged across $9.82 to $20.22, which puts the current price roughly 34% of the way up that band. Holders are ahead 21.5% over twelve months, but down 26.2% across the last three months.

On the chart it has slipped under both the 50-day ($13.73) and 200-day ($14.58) moving averages; RSI is 46, and the last 30 sessions moved at roughly 66% annualized volatility.

For the quarter ended Sep 2026 it reported $0.00 in revenue, and a net loss of $21.45M.

7 analysts follow the stock and the average call is "buy". The mean target, $27.71, sits 107.6% over where the stock trades.

This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.

Key statistics

Bid / Ask$12.00 / $15.84
Average price today$13.47
Volume2.09MAvg (90d) 1.98M
Turnover$28.14M
Turnover rate1.76%of shares outstanding
Volume ratio1.17vs. recent average pace
Day amplitude4.88%
Market cap$1.90B
Float market cap$1.59B
Shares outstanding118.81M
EPS (TTM)-$0.32
P/B6.29
Book value / share$2.12
Net profit (TTM)-$45.62M
Net assets$302.80M
30-day volatility66.1%annualized
Avg daily range (ATR)7.54%of price, 14 days
Max drawdown (1y)-39.1%-31.5% from 1y peak

Quote as of Nov 20, 2026 8:10 pm ET. Prices can lag the live tape. This is background information, not a recommendation.

BeStock Grade

C
BeStock Grade

Composite of 3 factors below, ranked against the 3734 U.S. stocks BeStock covers.

A
Valuation

Cheaper than usual on its own 5-year P/E history scores higher.

D
Momentum

Trading closer to its 52-week high than most peers scores higher.

B
Wall Street

7 analysts, consensus Buy.

How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.

Six-factor research snapshot

Overall percentile: 39.6 · 2026-11-22 08:27 UTC. Higher values indicate a stronger relative ranking.

FactorPercentile
Valuation—
Growth—
Profitability6.0
Momentum34.6
Financial health78.0
Analyst view91.6

Price forecast

What Wall Street analysts and Morningstar's fair-value model expect for the stock

Analyst price target (avg)$27.71+107.6% vs. current price
Consensus ratingBuy7 analysts covering
Morningstar fair value$16.45Price is below fair value

Wall Street’s average 12-month target is $27.71, 107.6% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $16.45, so shares trade 18.8% below that estimate. On earnings multiple, it sits in the 14th percentile of its own five-year valuation range (cheaper than usual).

Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.

Performance

Price return over each window, from adjusted daily and weekly closes

1 day
-2.7%
1 week
-2.2%
1 month
+3.2%
3 months
-26.2%
6 months
-5.5%
Year to date
+6.6%
1 year
+21.5%
Day range
$13.23$13.90
52-week range
$9.82$20.22

Technical signals

Full technicals →
Trend readStrong downtrend

0 bullish · 7 bearish of 7 signals

IndicatorValueSignal
Price vs 20-day average-2.9%Bearish
Price vs 50-day average-2.8%Bearish
Price vs 200-day average-8.5%Bearish
50-day vs 200-day50d below 200dBearish
RSI (14)46.2Bearish
MACD (12,26,9)-0.03Bearish
Bollinger band position35%Bearish

Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.

How TRVI ranks on BeStock

Market value#2694 of 3734
Closeness to 52-week high#2393 of 3724
Dollar volume today#1795 of 3734

Ranks are among the 3,734 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.

TRVI is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.

Since 2020-12-28, the strategy has returned 401.7% (183.6% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated daily — not a guarantee of future results, and not a BeStock recommendation.

Strategy Backtest

Pick a strategy above and run the backtest to see its simulated performance on TRVI.

Rule-based technical strategies computed from this stock’s own price history only. Signals use only data available through the prior trading day (no look-ahead), and trading costs, slippage and taxes aren’t modeled. A backtested rule performing well in the past is not a guarantee of future results — this is an educational illustration, not investment advice.

Community Sentiment on TRVI

No votes yet — be the first to weigh in.

Reader sentiment, not investment advice. One vote per visitor; click again to change it.

TRVI stock: common questions

Where is TRVI trading right now?

$13.35 is the latest print for TRVI, a move of -2.70% against yesterday's close of $13.72. Today's low and high so far: $13.23 and $13.90.

How large is Trevi Therapeutics by market value?

Equity value comes to $1.90B at the current price. By that measure it is number 2705 of the 3753 names in our coverage.

Where does TRVI sit in its 52-week range?

The year's floor is $9.82 and the ceiling $20.22. Shares are 34.0% away from that ceiling.

Does TRVI send cash back through a dividend?

Our data shows no dividend paid by Trevi Therapeutics over the trailing twelve months.

Do Wall Street analysts like TRVI?

Of 7 analysts, 100% say buy, 0% hold and 0% sell. Price targets average $27.71, with the most cautious at $23.00 and the most optimistic at $36.00.

BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.

Discussion

No comments yet — be the first to weigh in on TRVI.

Sign in to join the discussion.

Scroll to Top